This small scale, 2 day event will have important perspectives from industry, academia, and regulators as they take a detailed look at the current type 1 and type 2 diabetes drug scene and give an analysis of the future outlook. Attendees will not only learn about the scientific, clinical, and regulatory challenges, but also how to implement strategies that apply to long-term success. The aim of this event is to allow participants to gather up-to-date information necessary to make strategic decisions regarding developing early-phase anti-diabetic drugs while satisfying regulatory requirements.
Why Attend?
- Discover the most efficient methods of creating a pre-clinical program to get approval for FIH studies.
- Meet highly experienced experts that are directly involved in anti-diabetes trial design and implementation.
- Learn about the evolving regulatory requirements that need to be addressed in an early development program.
- Find out what clinical development strategies potential investors and partners look for while assessing the potential value of an experimental therapeutic.
- Understand the impact of planning the early stages for therapy sustainability in a diverse and complex diabetic population.
Who Will Benefit? Experienced executives from Pharma, Biotechs and Academia involved in oncology drug development:
VPs, Professors, Senior Directors and Managers involved in biologics, small molecules, discovery, pre-clinical development, exploratory development, early phase clinical development, clinical operations, clinical science, clinical pharmacology, biomarkers, licensing, translational medicine, regulatory affairs, therapy area heads, and R&D 
